Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer.

Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer.

Afficher d'autres versions (1)

OBJECTIVES: Reports have suggested that a reduction in tumour 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) examination during or after neoadjuvant chemotherapy may predict pathological response in oesophageal cancer. Our aim was to determine whether metabolic response pr...

Description complète

Détails bibliographiques
Auteurs principaux:	Gillies, R, Middleton, MR, Blesing, C, Patel, K, Warner, N, Marshall, R, Maynard, N, Bradley, K, Gleeson, F
Format:	Journal article
Langue:	English
Publié:	2012

Documents similaires

Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer
par: Gillies, R, et autres
Publié: (2012)

Challenges in assessing response of oesophageal cancer to neoadjuvant therapy, and the potential of composite PET-CT and multimodal metrics.
par: Findlay, J, et autres
Publié: (2017)

Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma.
par: Gillies, R, et autres
Publié: (2012)

Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma
par: Gillies, R, et autres
Publié: (2012)

Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.
par: Findlay, J, et autres
Publié: (2017)

Tumour expression of the DNA repair protein, XPF, predicts pathological response to neoadjuvant oxaliplatin chemotherapy in oesophageal cancer
par: Gillies, R, et autres
Publié: (2011)

Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer.
par: Gillies, R, et autres
Publié: (2011)

Additional benefit of 18F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer
par: Gillies, R, et autres
Publié: (2010)

Predicting pathological response of esophageal cancer to neoadjuvant chemotherapy: the implications of metabolic nodal response for personalised therapy
par: Findlay, J, et autres
Publié: (2016)

Role of adjuvant radiotherapy following neo-adjuvant chemotherapy (NACT) and surgery in oesophageal cancer - a multi-centre retrospective cohort study
par: Teoh, S, et autres
Publié: (2016)

The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma.
par: Chowdhury, F, et autres
Publié: (2008)

Neoadjuvant chemotherapy for oesophageal carcinoma - a risk factor for postoperative pneumonia?
par: Millo, J, et autres
Publié: (2003)

Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
par: Findlay, J, et autres
Publié: (2016)

Survival after curative chemoradiotherapy or neoadjuvant therapy and surgery converges in higher-risk patients with oesophageal cancer
par: Rana, M, et autres
Publié: (2021)

Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro‐oesophageal cancer
par: den Boer, RB, et autres
Publié: (2020)

Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
par: John M. Findlay, et autres
Publié: (2016-04-01)

A reply to evidence-based radiation oncology: oesophagus.
par: Gillies, R, et autres
Publié: (2010)

A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma
par: Kieran G. Foley, et autres
Publié: (2021-06-01)

Adjuvant radiotherapy following neo-adjuvant chemotherapy and surgery in oesophageal cancer: a retrospective cohort study of survival
par: Teoh, S, et autres
Publié: (2018)

Assessment of Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Using MRI and 18F FDG PET/CT
par: Reem Yusuf AlBuainain, et autres
Publié: (2025-01-01)

Role of F-18 FDG PET/CT in Predicting Response to Neoadjuvant Chemotherapy in Invasive Ductal Breast Cancer
par: Tarik Sengoz, et autres
Publié: (2023-04-01)

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy
par: Han Wonshik, et autres
Publié: (2011-10-01)

PET/CT staging and response evaluation of post-transplantation lymphoproliferative disease (PTLD).
par: Chowdhury, F, et autres
Publié: (2009)

Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy
par: A. G. M. T. Powell, et autres
Publié: (2020-08-01)

Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.
par: Alexander M Th Schmitz, et autres
Publié: (2017-01-01)

Direct comparison of PET/CT and MRI to predict the pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis
par: Lihua Chen, et autres
Publié: (2017-08-01)

Routinely staging gastric cancer with 18F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery
par: Findlay, J, et autres
Publié: (2019)

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma
par: Turkington, RC, et autres
Publié: (2019)

Whole transcriptome analysis of breast tumors during neoadjuvant chemotherapy: association with response to preoperative chemotherapy
par: M. K. Ibragimova, et autres
Publié: (2022-03-01)

Clinical value of SUVpeak-to-tumor centroid distance on FDG PET/CT for predicting neoadjuvant chemotherapy response in patients with breast cancer
par: Sun-pyo Hong, et autres
Publié: (2024-10-01)

Prognostic value of 18F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis
par: Sangwon Han, et autres
Publié: (2020-10-01)

Efficacy Of 18FDG-PET/CT In Predicting Response After Neoadjuvant Chemoradiation In Rectal Cancer
par: Narendra Pandit, et autres
Publié: (2023-08-01)

Comparison between body composition parameters and response to neoadjuvant chemotherapy by using pre-treatment PET CT in locally advanced breast cancer
par: Inci Kizildag Yirgin, et autres
Publié: (2020-01-01)

The Role of Pretreatment 18F-FDG PET/CT for Early Prediction of Neoadjuvant Chemotherapy Response in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
par: Yao J, et autres
Publié: (2021-10-01)

Predictors of complete response to neoadjuvant chemotherapy in non-metastatic bladder cancer
par: P. Sousa Passos, et autres
Publié: (2020-11-01)

Whole transcriptome analysis of breast tumors during neoadjuvant chemotherapy: association with response to preoperative chemotherapy. Additional material
par: M. K. Ibragimova, et autres
Publié: (2022-03-01)

Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study
par: Rui-Qin Zhou, et autres
Publié: (2023-05-01)

[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial
par: Giulia Polverari, et autres
Publié: (2020-10-01)

Correlation Between 18F-FDG PET/CT SUVmax and Clinicopathological Features, Neoadjuvant Chemotherapy Response in Invasive Ductal Breast Carcinoma Patients
par: LU Shengnan, et autres
Publié: (2019-02-01)

Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma
par: Willard Wong, et autres
Publié: (2021-07-01)